Recently, the National Medical Products Administration (NMPA) of China released approval information, granting marketing authorization for the Continuous Glucose Monitoring System (CGM, Model: IM-LHW-001) of InnoMind (Suzhou) Technology Co., Ltd. The registration certificate number is Guoxie Zhun 20263070620, classified as a Class III medical device, adding a new player to the domestic CGM market.
1. Product Composition: Consists of a disposable glucose sensor assembly (including sensor, sensor base, inserter), transmitter, and glucose monitoring application software (release version 1). Adopts a contract manufacturing model, with the production address located at Suzhou Life and Health Town Industrial Park Phase I.
2. Core Performance: The glucose sensor has a maximum wear time of 14 days, requires no user calibration, can collect and store interstitial fluid glucose values in real time, synchronously display blood glucose trends, and supports preset high/low blood glucose level alerts.
3. Scope of Application: Intended for use in adult diabetes patients aged 18 years and above for continuous or periodic monitoring of glucose levels in interstitial fluid, suitable for use in medical institutions and home environments. The registration certificate explicitly notes: The measurement results shall not be used as the basis for determining or adjusting diabetes patient treatment plans. The glucose sensor is for single use by a single patient only.
1. Regulatory Compliance: Class III medical devices represent the highest risk classification for medical devices in China, requiring rigorous safety and effectiveness evaluation by the NMPA. This approval marks the completion of the core regulatory approval process for the product's compliant market launch.
2. Product Positioning: The 14-day calibration-free long-term CGM represents the mainstream technical direction for current home blood glucose monitoring. The product is positioned for home auxiliary monitoring, with the clearly defined scope of application establishing the product's clinical boundaries and providing a basis for compliant promotion.
3. Market Landscape: The domestic CGM market continues to expand, and this new entrant further enriches market supply, providing diabetes patients with more tool options for home blood glucose management.
